NCT00324298View on ClinicalTrials.gov

Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

March 31, 2011

Conditions
Drug/Agent Toxicity by Tissue/OrganTesticular Germ Cell Tumor
Interventions
BIOLOGICAL

bleomycin sulfate

DRUG

cisplatin

DRUG

etoposide

PROCEDURE

management of therapy complications

Trial Locations (10)

SS16 5NL

Basildon University Hospital, Basildon

CB2 2QQ

Addenbrooke's Hospital, Cambridge

C03 3NB

Essex County Hospital, Colchester

IP4 5PD

Ipswich Hospital, Ipswich

LS9 7TF

Leeds Cancer Centre at St. James's University Hospital, Leeds

EC1A 7BE

Saint Bartholomew's Hospital, London

WIT 3AA

University College of London Hospitals, London

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

SM2 5PT

Royal Marsden - Surrey, Sutton

SS0 0RY

Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea

All Listed Sponsors
lead

Queen Mary University of London

OTHER

NCT00324298 - Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles | Biotech Hunter | Biotech Hunter